Alvotech announces positive top-line results from a pharmacokinetic study for avt03, a proposed biosimilar for prolia® and xgeva®

Alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic (pk) study for avt03, a biosimilar candidate to prolia® and xgeva®, which both contain denosumab.
ALVO Ratings Summary
ALVO Quant Ranking